Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Young Law Group Beefs Up Initiative Prosecuting Alleged Pharmaceutical Industry Kickbacks and Fraudulent Medicare and Medicaid Billings Prior to Obama-care
  • USA - English


News provided by

Young Law Group, P.C.

Jul 18, 2013, 05:00 ET

Share this article

Share toX

Share this article

Share toX

Young Law Group, P.C.
Young Law Group, P.C.

Philadelphia, PA (PRWEB) July 18, 2013 -- Medicare fraud is outrunning enforcement, a Center for Public Integrity study finds. “Federal agencies reported an estimated $115.3 billion in improper payments in fiscal year 2011, and more than half that figure was attributed to Medicare and Medicaid, according to the Government Accountability Office,” the Center for Public Integrity reported on July 1, 2013.

This YLG initiative also responds to Department of Justice achievements prosecuting false claims act violations in the pharmaceutical industry and other areas in the healthcare industry such as hospitals, physicians, pharmacies, long-term care facilities, and home health care.

In a news release on May 13, 2013, in one of the largest drug safety settlement to date with a generic drug manufacturer, the Department of Justice announced “that Ranbaxy USA Inc., a subsidiary of Indian generic pharmaceutical manufacturer Ranbaxy Laboratories Limited, pleaded guilty to felony charges relating to the manufacture and distribution of certain adulterated drugs made at two of Ranbaxy’s manufacturing facilities…and that Ranbaxy agreed to pay a criminal fine and forfeiture totaling $150 million and to settle civil claims under the False Claims Act and related State laws for $350 million” regarding government allegations that Ranbaxy fraudulently billed Medicare, Medicaid, and the Veterans Administration.

The massive settlement came about following whistleblower Dinesh Thakur’s unfailing efforts to alert first British and then American regulators of Ranbaxy’s alleged practices. When British regulators demurred on enforcement, Thakur approached the Food and Drug Administration, which took action resulting in the DOJ settlement and guilty plea. He receives $50M as part of the recovery under U.S. whistleblower law.

Ranbaxy settlement benefits are already flowing to states: New Jersey received $3.75M and Idaho is getting $400,000 according to a news report by northjersey.com on June 18, 2013. (northjersey.com/news/212029001_N_J__gets__3_75_million_in_drug_fraud_settlements.html)

In June, the Department of Justice announced litigation on behalf of the Food and Drug Administration in U.S. District Court for Western Louisiana (5:13-cv-1983) alleging that Sage Pharmaceuticals, Inc. allegedly violated federal law by manufacturing and distributing unapproved and misbranded pharmaceuticals.

“In many instances, these DOJ enforcement actions are yielding significant benefits for the public, notably recovery of more than $10.3 billion since January 2009 in cases involving fraud against federal health care programs thanks to whistleblowers,” Eric. L. Young said.

“A whistleblower like Dinesh Thakur deserves everyone’s thanks for alerting regulators to these alleged frauds,” Young continues. “It is particularly heartening that India is now putting whistleblower protections in place through the Securities and Exchange Board of India (Sebi). Indian pharmaceutical manufacturers produce ever increasing quantities of generic pharmaceuticals, which are and will be sold in America, and factories in Paonta Sahib, Batamandi, and Dewas, India have been among the most concerning for U.S. regulators.”

“U.S. Attorneys are also doing their part,” Young points out. U.S. Attorney Preet Bharara in the Southern District of New York filed suits in late April alleging that Swiss pharmaceutical manufacturer Novartis (ADR) engaged in multimillion dollar kickbacks to physicians from 2002 through 2011 inducing doctors to prescribe Novartis drugs that were paid for by Medicare and Medicaid, joining a False Claims Act qui tam lawsuit initially filed by Young Law Group, and a related complaint alleging kickbacks to twenty or more pharmacies in exchange for their switching transplant patients from competitor drugs to NOVARTIS’s drug, Myfortic.

As for billing Medicare and Medicaid for allegedly improper medical procedures, Barbara L. McQuade, U.S. Attorney for the Eastern District of Michigan, just announced a $4m settlement (case 0812339 settled July 10, 2013) in the U.S. District Court for the Eastern District of Michigan with Jackson Cardiology Associates and its owner, cardiologist Jashu Patel M.D., and Allegiance Health, a hospital, all located in Jackson, MI due to Dr. Julie A. Kovach’s whistleblower allegations that Dr. Patel and cardiologists at Jackson Cardiology Associates billed Medicare and Medicaid for allegedly inappropriate cardiac procedures.

“The complaint alleges that Dr. Patel and cardiologists employed by Jackson Cardiology Associates performed medically inappropriate cardiac procedures, including invasive catheterizations at Allegiance Health. Specifically, the evidence showed that Dr. Patel ordered catheterizations for patients based on findings from nuclear stress tests that he improperly read as positive. The government found that three-quarters of these patients had no significant heart blockages,” McQuade said in a press release (justice.gov/usao/mie/news/2013/2013_7_10_jpatel_HCF.html).

Dr. Kovach is entitled to a portion of the recovery.

Allegiance Health issued a statement saying it disagrees with the allegations and that it admits no wrongdoing. (prnewswire.com/news-releases/allegiance-health-reaches-agreement-on-allegations-by-department-of-justice-214992051.html)

The Department of Justice Complaint regarding Ranbaxy is Case 1:13-cr-00238-JFM, (justice.gov/iso/opa/resources/240201352412262032481.pdf)
The Justice Department settlement agreement is (justice.gov/opa/pr/2013/June/13-civ-695.html); attachments include (justice.gov/iso/opa/resources/5752013524122655233258.pdf), (justice.gov/iso/opa/resources/2932013524122712703563.pdf), and (justice.gov/iso/opa/resources/4692013524122723558271.pdf); U.S. Attorney Preet Bharara’s complaint regarding physicians is Case Number 11 Civ.0071 and his complaint regarding pharmacies is Case Number 11 Civ. 8196.

Young Law Group specializes in representing whistleblowers ("relators") throughout the United States and internationally in qui tam lawsuits brought under the False Claims Act. The False Claims Act allows private individuals to sue companies that are defrauding the federal government and to recover funds on the government's behalf.

Whistleblowers may be entitled to 15 percent to 30 percent of civil recoveries resulting
from a qui tam lawsuit.

Contact: Young Law Group by email by clicking on Mr. Young's name on the right or visit our website.

Eric L. Young, Young Law Group, P.C., http://www.eganyoung.com, (800) 590-4116, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.